How much funding has Amplyx Pharmaceuticals raised?

Amplyx Pharmaceuticals has raised $139.2M in total funding, most recently a series c round.

Who are Amplyx Pharmaceuticals's investors?

Amplyx Pharmaceuticals's investors include Pfizer Ventures, Sofinnova Investments, RiverVest Venture, New Enterprise Associates, Lundbeckfonden Ventures, Arix Bioscience.

When was Amplyx Pharmaceuticals founded?

Amplyx Pharmaceuticals was founded in 2006.

Where is Amplyx Pharmaceuticals headquartered?

Amplyx Pharmaceuticals is headquartered in San Diego, California, United States.

What industry is Amplyx Pharmaceuticals in?

Amplyx Pharmaceuticals operates in Antifungal Drugs, Biotech.

How many employees does Amplyx Pharmaceuticals have?

Amplyx Pharmaceuticals has 11-50 employees.

Amplyx Pharmaceuticals

Acquired

San Diego, United States · Founded 2006 · $139.2M raised

Antifungal Drugs

Biotech

Headquarters: San Diego, California
Employees: 11–50
Founded: 2006
Business Model: B2B

Website: amplyx.com
Total Funding: $139.2M
Last Round: $90.0M Series CAug 2017
Rounds: 2

About

Amplyx Pharmaceuticals was a San Diego-based clinical-stage biopharmaceutical company founded in 2006 on a mission to save lives by developing a novel class of antifungal medicines to overcome the severe limitations of existing treatments. Its lead compound, fosmanogepix (APX001), represented a first-in-class antifungal mechanism targeting the Gwt1 enzyme. In April 2021, Amplyx was acquired by Pfizer Inc., which continued development of fosmanogepix as part of its infectious disease pipeline.

Summary

Amplyx Pharmaceuticals is an Antifungal Drugs company based in San Diego, United States, founded in 2006. It has raised $139.2M in total across 2 rounds, most recently a $90.0M Series C round in Aug 2017. Investors include Pfizer Ventures, Sofinnova Investments and RiverVest Venture.